arrow
I

Ibrahim Aldoss

city of hope
H指数:46
被引数:8,001

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy

B细胞活化因子受体在B淋巴母细胞白血病中的表达:流式细胞术分析及其靶向治疗意义

2026-08-210
PRE
Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy

白血病患者接受CD19 CAR T细胞治疗后的长期应答的免疫代谢决定因素

2026-02-200
OAAI
Impact of Itacitinib Exposure on Immune Reconstitution and Cytokine Profile Following HLA-Matched Allogeneic Hematopoietic Cell Transplantation (HCT) with Tacrolimus, Sirolimus, and Itacitinib GVHD Prophylaxis
2026-02-030
PRE
Recognition, prevention, and management of adverse events associated with asparaginase/pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel

急性淋巴细胞白血病成人患者应用天冬酰胺酶/聚乙二醇化天冬酰胺酶治疗相关不良事件的识别、预防与管理:专家共识

2025-12-012
OAAI
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib

纳拉蒂布或伊马替尼治疗新诊断的费城染色体阳性急性淋巴细胞白血病患者中,临床反应和治疗耐受性对健康相关生活质量的影响

2025-10-100
OA
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden

细胞减灭术对高肿瘤负荷复发或难治性B-ALL患者博纳吐莫单抗疗效的影响

2025-09-090
PRE
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia

靶向治疗和免疫疗法在TP53突变急性淋巴细胞白血病患者中的疗效

2025-09-010
PRE
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

门诊Brexucabtagene autoleucel在B细胞急性淋巴细胞白血病和套细胞淋巴瘤中的应用

2025-08-200
PREAI